Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delivering enhanced testosterone replacement therapy through nanochannels.

Silvia Ferrati1, Eugenia Nicolov, Shyam Bansal

  • 1The Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.

Advanced Healthcare Materials
|October 3, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Inflammatory Preconditioning Reprograms Mesenchymal Stromal Cell-Derived Extracellular Vesicles into Distinct Functional States for Immunomodulation and Wound Healing.

Stem cells and development·2026
Same author

Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.

Biomedical microdevices·2026
Same author

Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Overcoming intratumoral transport barriers: Advances in local immunotherapy delivery platforms.

Advanced drug delivery reviews·2026
Same author

Pancreatic Islet Isolation and Purification from Lewis Rats Using Enzymatic Digestion and Density-Gradient Separation.

Journal of visualized experiments : JoVE·2026

This study introduces a novel nanochannel implant for sustained testosterone release, offering a potential breakthrough treatment for male hypogonadism. The implant ensures stable hormone levels, improving quality of life for patients requiring long-term testosterone replacement therapy.

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Materials Science

Background:

  • Male hypogonadism presents significant quality of life issues, necessitating lifelong testosterone replacement therapy.
  • Current testosterone therapies often face challenges with sustained and consistent delivery.
  • An implantable system offers a promising alternative for long-term, stable hormone release.

Purpose of the Study:

  • To investigate an implantable nanochannel system for sustained testosterone delivery.
  • To evaluate testosterone and testosterone:2-hydroxypropyl-β-cyclodextrin (TES:HPCD) complex release kinetics.
  • To assess the in vivo efficacy and safety of the nanochannel implant for treating hypogonadism.

Main Methods:

  • In vitro release tests using HPLC to quantify testosterone and TES:HPCD complexes (1:1 and 1:2 molar ratios).
Keywords:
androgen deficiencycyclodextrinnanochannel implantssustained releasetestosterone

Related Experiment Videos

  • Bioactivity assessment using LNCaP/LUC cell luminescence.
  • In vivo evaluation in castrated rats measuring testosterone, luteinizing hormone (LH), and follicle stimulating hormone (FSH) levels via LC/MS and multiplex assay over 30 days.

    • Main Results:

    • The 1:2 TES:HPCD complex demonstrated significantly higher testosterone solubility (10-15x) and in vitro release (25-30x).
    • The nanochannel implant achieved sustained and clinically relevant in vivo release kinetics.
    • Physiologically stable plasma levels of testosterone, LH, and FSH were attained in treated rats.

    Conclusions:

    • The 1:2 TES:HPCD nanochannel implant provides long-term, steady release of testosterone.
    • This system represents a potential major breakthrough for the treatment of male hypogonadism.
    • The implantable nanochannel system offers a promising alternative to conventional testosterone replacement therapies.